2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2474

Psychometric Properties of the Social Appearance Anxiety Scale in Patients with Limited and Diffuse Systemic Sclerosis: Analysis from the Scleroderma Patient-Centered Intervention Network Cohort
Abstract Number: 2545

Psychometric Testing of the Valued Life Activities Questionnaire in People with Rheumatoid Arthritis in the UK: Rasch Analysis
Abstract Number: 2303

Psychometrics of Online Administration of Fibromyalgia Impact Questionnaire – Revised
Abstract Number: 2458

Psychostimulant-Induced Vasculopathy: A Retrospective Study in a Pediatric Rheumatology Clinic
Abstract Number: 2374

Pulmonary Arterial Hypertension in Patients with Anti-PM-Scl Antibody
Abstract Number: 3005

Pulmonary Arterial Hypertension-Associated Single Nucleotide Polymorphisms of Hypoxia-Inducible Factor-3a Gene Cause Constitutive Activation of the Endothelin-1 Gene Promoter
Abstract Number: 1337

Pulmonary Computed Tomography Changes in Patients with Rheumatoid Arthritis
Abstract Number: 2966

Pulmonary Involvement in Systemic Sclerosis at Initial Presentation: A Single Center Experience
Abstract Number: 1600

Pulmonary Manifestations in Early Rheumatoid Arthritis: A 6 Month Follow up Study
Abstract Number: 252

Pyrin (MEFV) Mutations in New York: Revisiting the Mount Sinai Experience with Periodic Fever and Serositis
Abstract Number: 1126

Pyrrolopyrimidine Derivatives That Inhibit BAFF Binding to Its Receptor, BR3, Decrease IgG Production By B Cells in Vitro and in Vivo Model of Autoimmune Diseases
Abstract Number: 2403

Quadriceps Muscle Weakness and the Risk of Knee Cartilage Loss on MRI in a Population-Based Cohort with Knee Pain
Abstract Number: 1479

Qualitative Assessment of Patient Important Long-Term Outcomes in Juvenile Idiopathic Arthritis
Abstract Number: 472

Quality Assessment in Clinical Management of Patients with Rheumatoid Arthritis. Are We Using the “Treat to Target” Strategy?
Abstract Number: 2216

Quality Assessment of Websites Providing Educational Content about Rheumatoid Arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].